Morgan Stanley Capricor Therapeutics, Inc. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 551,694 shares of CAPR stock, worth $3.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

551,694

Previous 550,581 0.2%

Holding current value

$3.11 Million

Previous $5.47 Million 26.74%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$5.94 - $11.42 $6,611 - $12,710	1,113 Added 0.2%	551,694 $4.01 Million
Q2 2025 Aug 15, 2025	SELL	$6.34 - $14.23 $1.68 Million - $3.77 Million	-264,784 Reduced 32.47%	550,581 $5.47 Million
Q1 2025 May 15, 2025	BUY	$9.49 - $16.11 $1.74 Million - $2.96 Million	183,611 Added 29.06%	815,365 $7.74 Million
Q4 2024 Feb 14, 2025	BUY	$12.9 - $21.99 $6.45 Million - $11 Million	500,238 Added 380.36%	631,754 $8.75 Million
Q3 2024 May 14, 2025	BUY	$3.56 - $15.21 $186,262 - $795,802	52,321 Added 66.07%	131,516 $2 Million
Q3 2024 Nov 14, 2024	BUY	$3.56 - $15.21 $186,262 - $795,802	52,321 Added 66.07%	131,516 $2 Million
Q2 2024 May 14, 2025	SELL	$4.63 - $7.09 $2.56 Million - $3.92 Million	-552,559 Reduced 87.46%	79,195 $377,000
Q2 2024 Oct 17, 2024	SELL	$4.63 - $7.09 $150,021 - $229,730	-32,402 Reduced 29.03%	79,195 $377,000
Q2 2024 Aug 14, 2024	SELL	$4.63 - $7.09 $150,021 - $229,730	-32,402 Reduced 29.03%	79,195 $377,000
Q1 2024 Oct 17, 2024	BUY	$3.61 - $6.88 $116,971 - $222,925	32,402 Added 40.91%	111,597 $757,000
Q1 2024 Aug 16, 2024	BUY	$3.61 - $6.88 $230,711 - $439,693	63,909 Added 134.01%	111,597 $757,000
Q1 2024 May 15, 2024	BUY	$3.61 - $6.88 $230,711 - $439,693	63,909 Added 134.01%	111,597 $757,000
Q4 2023 Aug 16, 2024	SELL	$2.71 - $5.08 $85,383 - $160,055	-31,507 Reduced 39.78%	47,688 $233,000
Q4 2023 Feb 13, 2024	BUY	$2.71 - $5.08 $13,550 - $25,400	5,000 Added 11.71%	47,688 $233,000
Q3 2023 Nov 15, 2023	SELL	$3.42 - $7.85 $35,718 - $81,985	-10,444 Reduced 19.66%	42,688 $145,000
Q2 2023 Aug 14, 2023	BUY	$3.76 - $5.05 $38,103 - $51,176	10,134 Added 23.57%	53,132 $253,000
Q1 2023 May 15, 2023	BUY	$3.78 - $5.03 $1,307 - $1,740	346 Added 0.81%	42,998 $181,000
Q4 2022 Feb 14, 2023	BUY	$3.36 - $6.55 $9,912 - $19,322	2,950 Added 7.43%	42,652 $164,000
Q3 2022 Nov 14, 2022	BUY	$3.61 - $6.08 $6,570 - $11,065	1,820 Added 4.8%	39,702 $238,000
Q2 2022 Oct 27, 2022	BUY	$2.89 - $4.51 $11,955 - $18,657	4,137 Added 12.26%	37,882 $132,000
Q2 2022 Aug 15, 2022	BUY	$2.89 - $4.51 $11,955 - $18,657	4,137 Added 12.26%	37,882 $132,000
Q1 2022 Oct 27, 2022	SELL	$2.83 - $5.68 $11,707 - $23,498	-4,137 Reduced 10.92%	33,745 $116,000
Q1 2022 May 13, 2022	BUY	$2.83 - $5.68 $1,511 - $3,033	534 Added 1.61%	33,745 $116,000
Q4 2021 Feb 14, 2022	SELL	$2.89 - $4.16 $50,436 - $72,600	-17,452 Reduced 34.45%	33,211 $98,000
Q3 2021 Nov 15, 2021	BUY	$3.8 - $5.23 $192,519 - $264,967	50,663 New	50,663 $204,000

Others Institutions Holding CAPR

# of Institutions

142

Shares Held

13.3M

Call Options Held

Put Options Held

2.76M

View Full List

About CAPRICOR THERAPEUTICS, INC.

Ticker CAPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,346,200
Market Cap $137M
Description
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...

More about CAPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account